Ready to play
Ready to play
The U.S. Food and Drug Administration (FDA) announced its approval of a standalone immunotherapy drug for the treatment of a specific type of locally advanced rectal cancer. This approval follows a clinical trial showing that 71% of participants did not require surgery or additional treatments, and their cancer remained stable for over 26 months. This therapy, which belongs to the class of immune checkpoint inhibitors, offers a non-surgical option that can help patients preserve their organs and maintain their normal functions. It also reduces long-term complications associated with traditional surgeries, such as bowel, sexual, and fertility issues. However, this treatment is suitable only for tumors with certain molecular characteristics (dMMR and MSI-H) that make them more responsive to immunotherapy. Long-term results are still under study, and ongoing monitoring is necessary. While the therapy may reduce the need for surgery in multiple cases, it does not completely eliminate the possibility that some patients might still require surgery or experience disease recurrence, with potential side effects including infections and immune-related complications.
Notice: This Is an AI-Generated Summary
Comments (0)